The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium co-treated with Zinc] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein]
Aluminum results in decreased activity of ACO2 protein Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein] Aluminum results in decreased expression of and results in decreased activity of ACO2 protein
caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein] Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA]
APP protein binds to Aluminum [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] [APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA Aluminum results in increased expression of APP mRNA APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]
Aluminum affects the folding of ATXN3 protein polymorphism Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]
BAX protein affects the susceptibility to Aluminum [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein] [aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] Aluminum results in decreased expression of BBOX1 protein
[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein] [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein]
Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein] [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein]
Aluminum results in increased expression of CASP3 [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of CASP3 protein [Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA]
[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein]
[Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein
Aluminum results in decreased activity of CAT protein [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein] [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased activity of CAT protein; CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein] Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein
Aluminum results in decreased expression of CHAT protein Aluminum results in decreased activity of CHAT protein APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA] Aluminum results in decreased expression of COL1A1 mRNA
[Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA]
[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein
[[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein
Aluminum affects the folding of F8 protein [Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein
Aluminum results in increased expression of GFAP protein [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of IL6 protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein] [Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein]
Aluminum results in increased phosphorylation of MAPT protein [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
Aluminum results in increased expression of MMP9 protein [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA
Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFE2L2 protein
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFKB1 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFKB1 protein
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]
[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA]
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA]
Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA]
Aluminum results in increased expression of TNF protein [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA] [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of TNF protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein] [Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA
[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum TF protein results in increased uptake of Aluminum Aluminum binds to TF protein; TF protein binds to Aluminum TRF protein binds to Aluminum
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein Aluminum results in increased expression of VIM mRNA
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein]
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
Aluminum Hydroxide results in increased expression of CD86 protein Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 mRNA]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 protein]
Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]; Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of GATA3 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of GATA3 mRNA]
Aluminum Hydroxide results in increased expression of IL13 mRNA [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein] [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
Aluminum Hydroxide results in increased expression of IL2 mRNA [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]
Aluminum Hydroxide results in increased expression of IL4 mRNA [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein] IL4 protein affects the susceptibility to Aluminum Hydroxide Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]
Aluminum Hydroxide results in increased expression of IL5 mRNA [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R mRNA]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK1 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK1 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK2 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK2 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA]
NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of STAT3 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of STAT3 protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein]
TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFRSF4 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFRSF4 mRNA]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFSF4 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFSF4 mRNA]
[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP protein]
Aluminum Oxide results in increased expression of CASP3 Aluminum Oxide results in increased expression of CASP3 mRNA sesamol inhibits the reaction [Aluminum Oxide results in increased expression of CASP3 mRNA]
Aluminum Oxide results in decreased activity of CAT protein sesamol inhibits the reaction [Aluminum Oxide results in decreased activity of CAT protein]
Aluminum Oxide results in increased expression of IL1B mRNA Aluminum Oxide results in increased secretion of IL1B protein [Aluminum Oxide co-treated with Nanotubes, Carbon] results in decreased secretion of IL1B protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein] [Aluminum Oxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
Aluminum Oxide results in increased expression of IL6 mRNA; Aluminum Oxide results in increased expression of IL6 protein [Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of IL6 protein Aluminum Oxide results in decreased secretion of IL6 protein Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL6 protein]
[Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein; [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein alternative form
Aluminum Oxide results in decreased activity of SOD1 protein sesamol inhibits the reaction [Aluminum Oxide results in decreased activity of SOD1 protein]
Aluminum Oxide results in increased expression of SPP1 mRNA [Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of SPP1 protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased expression of SPP1 mRNA]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein] Aluminum Oxide results in decreased secretion of SPP1 protein [Aluminum Oxide co-treated with Nanotubes, Carbon] inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
Aluminum Oxide results in increased activity of TNF protein sesamol inhibits the reaction [Aluminum Oxide results in increased expression of TNF mRNA] [Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased expression of TNF mRNA Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of TNF protein] Aluminum Oxide affects the secretion of TNF protein
[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein]
aluminum sulfate results in increased expression of IL1B mRNA [Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Sodium inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of IL1B protein]; NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; Resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]
aluminum sulfate results in increased expression of NFKB1 mRNA [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]
aluminum fluoride results in increased phosphorylation of CD3E protein Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3E protein]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium co-treated with Zinc] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein]
Aluminum results in decreased activity of ACO2 protein Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein] Aluminum results in decreased expression of and results in decreased activity of ACO2 protein
caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein] Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA]
APP protein binds to Aluminum [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] [APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA Aluminum results in increased expression of APP mRNA APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]
Aluminum affects the folding of ATXN3 protein polymorphism Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]
BAX protein affects the susceptibility to Aluminum [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein] [aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] Aluminum results in decreased expression of BBOX1 protein
[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein] [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein]
Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein] [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein]
Aluminum results in increased expression of CASP3 [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of CASP3 protein [Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA]
[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein]
[Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein
Aluminum results in decreased activity of CAT protein [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein] [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased activity of CAT protein; CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein] Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein
Aluminum results in decreased expression of CHAT protein Aluminum results in decreased activity of CHAT protein APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA] Aluminum results in decreased expression of COL1A1 mRNA
[Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA]
[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein
[[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein
Aluminum affects the folding of F8 protein [Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein
Aluminum results in increased expression of GFAP protein [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of IL6 protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein] [Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein]
Aluminum results in increased phosphorylation of MAPT protein [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
Aluminum results in increased expression of MMP9 protein [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA
Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFE2L2 protein
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFKB1 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFKB1 protein
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]
[aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA]
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA]
Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA]
Aluminum results in increased expression of TNF protein [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA] [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of TNF protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein] [Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA
[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum TF protein results in increased uptake of Aluminum Aluminum binds to TF protein; TF protein binds to Aluminum TRF protein binds to Aluminum
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein Aluminum results in increased expression of VIM mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]
boric acid results in decreased expression of BAX mRNA boric acid results in increased expression of BAX mRNA [boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein
boric acid results in increased expression of BCL2 mRNA boric acid results in decreased expression of BCL2 mRNA [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA] boric acid results in increased expression of CASP3 mRNA boric acid results in decreased expression of CASP3 mRNA
[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein] boric acid results in decreased activity of CAT protein boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]
boric acid results in increased expression of CCND1 mRNA boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]
boric acid results in increased phosphorylation of EIF2S1 protein EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IFNG mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL10 mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL1B mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA] [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL6 mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] boric acid results in increased expression of INS2 mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]
boric acid results in increased expression of PCNA protein [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]
boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] boric acid results in decreased expression of TNF mRNA [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of TNF mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein] boric acid results in increased secretion of TNF protein boric acid results in increased expression of TNF mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Boron inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA]
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein] [Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]] Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein Bortezomib results in decreased activity of ABCB1 protein
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein]
Bortezomib affects the localization of AIFM1 protein [Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form] Bortezomib results in decreased activity of AKT1 protein
Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein]
pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein] Bortezomib results in increased expression of ATF2 mRNA
ATF3 results in increased susceptibility to Bortezomib [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA] Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein ATF4 results in decreased susceptibility to Bortezomib
ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein]
[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] Bortezomib results in increased expression of BAK1 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]] Bortezomib results in increased expression of BAX protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein Bortezomib results in increased expression of BCL2A1A protein
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein] Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein Bortezomib results in increased expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Bortezomib
[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein] Bortezomib results in increased expression of BCL2L11 protein Bortezomib results in increased activity of BCL2L11 protein BCL2L11 results in increased susceptibility to Bortezomib
BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] BECN1 protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased cleavage of BID protein [Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
BIK results in increased susceptibility to Bortezomib Bortezomib results in increased expression of BIK protein Bortezomib results in increased activity of BIK protein
Bortezomib results in decreased expression of BIRC2 protein [geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
Bortezomib results in decreased expression of BIRC3 protein Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein [Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein] Bortezomib results in increased expression of BIRC5 protein
Bortezomib results in decreased expression of BRCA1 mRNA BRCA1 mutant form results in increased susceptibility to Bortezomib Bortezomib results in decreased ubiquitination of BRCA1 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] BRCA1 gene mutant form results in increased susceptibility to Bortezomib BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein] [Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein] CASP2 results in increased susceptibility to Bortezomib Bortezomib results in increased cleavage of CASP2 protein
Bortezomib results in increased activity of CASP3 protein Bortezomib results in increased cleavage of CASP3 protein Bortezomib results in increased expression of CASP3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] CASP4 protein results in increased susceptibility to Bortezomib Bortezomib results in increased activity of CASP4 protein
Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein]
[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein] Bortezomib results in increased activity of CASP7 protein
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein] Bortezomib results in increased expression of CASP9 protein CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein Bortezomib results in decreased expression of CCL3 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein Bortezomib results in increased expression of CCNB1 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein]
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein] Bortezomib results in increased phosphorylation of CDK1 protein Bortezomib results in increased activity of CDK1 protein Bortezomib results in decreased activity of CDK1 protein
Bortezomib results in increased stability of CDKN1A protein [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel] CDKN1A results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1B protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein] Bortezomib results in increased stability of CDKN1B protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] Bortezomib results in decreased expression of CEBPB mRNA 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib affects the expression of CFLAR protein [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein] CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA Bortezomib results in increased expression of CRYAB mRNA
2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein]
Bortezomib results in increased expression of CXCL8 mRNA Bortezomib inhibits the reaction [Vorinostat results in increased expression of CXCL8 mRNA]; SC 514 inhibits the reaction [Bortezomib results in increased secretion of CXCL8 protein]
Bortezomib results in increased expression of CXCL2 mRNA Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]
[Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein Bortezomib affects the localization of CYCS protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein] Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein] DDIT3 results in decreased susceptibility to Bortezomib
Bortezomib affects the localization of DIABLO protein Bortezomib results in increased localization of DIABLO protein Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]
Bortezomib results in decreased expression of EGR2 mRNA Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein
Bortezomib results in increased phosphorylation of EIF2AK3 protein Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in decreased susceptibility to Bortezomib
Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein] ERN1 results in decreased susceptibility to Bortezomib
Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein]
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
Bortezomib results in decreased expression of ESRRA mRNA Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
Bortezomib results in increased expression of F3 protein [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein
[Bortezomib co-treated with vorinostat] results in increased expression of FAS protein Bortezomib results in decreased expression of FAS mRNA Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein
[Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein] Bortezomib results in increased expression of FASLG protein
Bortezomib results in increased expression of GADD45A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA
Bortezomib results in increased expression of GADD45B mRNA Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]
Bortezomib results in increased expression of GDF15 mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein]
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form] Bortezomib results in decreased phosphorylation of H2AX protein Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein HMOX1 protein results in increased susceptibility to Bortezomib
ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
Bortezomib results in increased expression of HSF1 mRNA Bortezomib results in increased activity of HSF1 protein Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]
HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein] Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter] HSPA1A protein results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA1A mRNA
Bortezomib results in increased expression of HSPA1B mRNA HSPA1B protein affects the susceptibility to Bortezomib HSPA1B protein results in decreased susceptibility to Bortezomib
Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein] Bortezomib results in increased expression of HSPA5 mRNA HSPA5 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein Bortezomib results in decreased expression of ICAM1 mRNA
[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased susceptibility to IGF2 protein
Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Bortezomib results in decreased expression of IKBKB mRNA
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone] Bortezomib results in increased expression of IL6 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA] Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] Bortezomib results in decreased expression of IL6 mRNA Bortezomib results in decreased secretion of IL6 protein
Bortezomib results in increased expression of IL7R mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA
Bortezomib results in decreased expression of IRF4 protein 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein]
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein] Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form Bortezomib results in decreased expression of JUN mRNA
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein]
[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein] Bortezomib results in decreased activity of MAPK1 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein]
[Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein] Bortezomib results in decreased activity of MAPK3 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
Bortezomib results in increased phosphorylation of MAPK9 protein [Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein] Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein] MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein] Bortezomib affects the expression of MDM2 protein
Bortezomib results in decreased expression of MKI67 protein [Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein]
[Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein] Bortezomib results in increased expression of MYC protein Bortezomib results in decreased expression of MYC protein
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein Bortezomib results in increased expression of NFE2L2 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA] Bortezomib results in increased activity of NFE2L2 protein
[Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]] Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein
Bortezomib results in decreased cleavage of NFKB2 protein Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein] Bortezomib results in increased stability of NFKBIA protein Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form Bortezomib results in decreased degradation of NFKBIA protein
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA] Bortezomib results in increased stability of NFKBIE protein
Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA] Bortezomib results in increased expression of NLRP12 mRNA
Bortezomib results in increased expression of NOS1 protein Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]
Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib] NPM1 protein affects the susceptibility to Bortezomib
Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]
NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of NUPR1 mRNA
[alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with Vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein] Bortezomib results in increased expression of PARP1 protein
Bortezomib results in increased expression of PCYT1A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA
Bortezomib binds to and results in decreased activity of PGR protein; Bortezomib inhibits the reaction [Promegestone results in increased activity of PGR protein]
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA; [Bortezomib co-treated with arsenic trioxide] results in increased expression of PMAIP1 protein; [Bortezomib co-treated with vorinostat] results in increased expression of PMAIP1 protein; [nutlin 3 co-treated with Bortezomib] results in increased expression of PMAIP1 protein; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein] PMAIP1 protein results in increased susceptibility to Bortezomib; PMAIP1 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of PMAIP1 mRNA; Bortezomib results in increased expression of PMAIP1 protein Bortezomib results in decreased expression of PMAIP1 mRNA
Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein]
[arsenic trioxide co-treated with Bortezomib] results in increased cleavage of and results in increased activity of PRKCD protein; Bortezomib promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein]
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of PRKDC protein] Bortezomib results in decreased expression of PRKDC mRNA
Bortezomib binds to PSMB5 protein PSMB5 protein affects the susceptibility to Bortezomib Bortezomib results in increased expression of PSMB5 mRNA PSMB5 gene mutant form results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of PTGS2 mRNA; Bortezomib results in increased expression of PTGS2 protein Bortezomib promotes the reaction [capillarisin results in decreased expression of PTGS2 protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]
[Bortezomib co-treated with Butyrates] results in decreased expression of RAF1 protein; [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of RAF1 protein Bortezomib results in decreased expression of RAF1 protein
[Bortezomib co-treated with Butyrates] results in increased degradation of RB1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of RB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
[Bortezomib co-treated with Arsenic Trioxide] results in decreased activity of RELA protein; [Bortezomib co-treated with Doxorubicin] results in decreased phosphorylation of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of and results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of RELA protein; [Bortezomib co-treated with Vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [Resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [romidepsin results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]] Bortezomib results in decreased expression of RELA mRNA; Bortezomib results in decreased expression of RELA protein Bortezomib results in decreased activity of RELA protein
Bortezomib results in decreased expression of SKP2 protein Cisplatin promotes the reaction [Bortezomib results in decreased expression of SKP2 protein]
[Bortezomib inhibits the reaction [Cisplatin results in decreased expression of SLC31A1 protein]] which results in increased uptake of Cisplatin; [Bortezomib results in decreased degradation of SLC31A1 protein] which results in increased uptake of Platinum; Bortezomib inhibits the reaction [Cisplatin results in decreased expression of SLC31A1 protein]
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of SOD2 mRNA SOD2 gene SNP results in increased susceptibility to Bortezomib
[alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein; [resveratrol co-treated with Bortezomib] results in decreased phosphorylation of STAT3 protein; Bortezomib promotes the reaction [Capsaicin results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of STAT3 protein]; Bortezomib results in increased expression of and results in increased phosphorylation of STAT3 protein Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA]
Bortezomib inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of and results in decreased phosphorylation of STK11 protein]; Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of STK11 protein]
Bortezomib results in increased activity of and results in increased localization of STK4 protein; leptomycin B promotes the reaction [Bortezomib results in increased activity of STK4 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein] STK4 protein results in increased susceptibility to Bortezomib; STK4 results in increased susceptibility to Bortezomib
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased expression of STS mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; Bortezomib binds to and results in decreased activity of THRA protein
Bortezomib promotes the reaction [arsenic trioxide results in increased expression of TICAM2 mRNA] Bortezomib results in increased expression of TICAM2 mRNA
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of TLR2 mRNA] Bortezomib results in increased expression of TLR2 mRNA
[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of TNF protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]] Bortezomib results in increased expression of TNF mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA] Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Bortezomib inhibits the reaction [TNF protein results in increased activity of UPP1 protein]; Bortezomib inhibits the reaction [TNF protein results in increased expression of UPP1 mRNA]
Bortezomib affects the expression of TNFRSF10A mRNA; Bortezomib affects the expression of TNFRSF10A protein Bortezomib results in increased localization of TNFRSF10A protein Bortezomib results in increased expression of TNFRSF10A protein Bortezomib results in decreased expression of TNFRSF10A protein [Bortezomib co-treated with arsenic trioxide] results in increased expression of TNFRSF10A protein; [Bortezomib results in increased localization of TNFRSF10A protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; Brefeldin A inhibits the reaction [Bortezomib results in increased localization of TNFRSF10A protein]
[arsenic trioxide co-treated with Bortezomib] results in increased expression of TNFSF10 mRNA; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib results in increased localization of TNFRSF10A protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; [Bortezomib results in increased localization of TNFRSF10B protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of XIAP protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]; Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein; Brefeldin A affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of XIAP protein] BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] Bortezomib results in decreased expression of TNFSF10 mRNA; Bortezomib results in decreased expression of TNFSF10 protein
Bortezomib inhibits the reaction [4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione results in increased degradation of and results in decreased expression of TOP2B protein]; Bortezomib inhibits the reaction [Razoxane results in increased degradation of and results in decreased expression of TOP2B protein]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]
Bortezomib results in increased expression of TP53 protein Bortezomib affects the activity of TP53 protein Bortezomib results in increased activity of TP53 protein [SCIO-469 co-treated with Bortezomib] results in increased expression of TRP53 protein [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein; [vorinostat co-treated with Bortezomib] results in increased expression of TP53 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]; Bortezomib results in increased phosphorylation of and results in increased localization of TP53 protein; Caffeine inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased expression of TP53 protein]; TP53 protein affects the susceptibility to [irinotecan co-treated with Bortezomib] Bortezomib results in increased stability of TP53 protein
TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib inhibits the reaction [TNF protein results in increased activity of UPP1 protein]; Bortezomib inhibits the reaction [TNF protein results in increased expression of UPP1 mRNA] Bortezomib results in decreased activity of UPP1 protein
Bortezomib results in decreased expression of VEGFA protein [Curcumin co-treated with Bortezomib] results in decreased expression of VEGFA protein; Bortezomib promotes the reaction [docetaxel results in decreased expression of VEGFA protein]; CGC 11093 promotes the reaction [Bortezomib results in decreased expression of VEGFA protein]; docetaxel promotes the reaction [Bortezomib results in decreased expression of VEGFA protein]
[ricolinostat co-treated with Bortezomib] results in increased expression of XBP1 protein alternative form; Bortezomib inhibits the reaction [Brefeldin A results in increased activity of XBP1 protein] Bortezomib results in increased expression of XBP1 protein alternative form Bortezomib results in increased activity of XBP1 protein
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XIAP protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XIAP protein; [Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein; [Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein; [romidepsin co-treated with Bortezomib] results in decreased expression of XIAP protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of XIAP protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of XIAP protein] Bortezomib results in increased expression of XIAP mRNA; Bortezomib results in increased expression of XIAP protein Bortezomib affects the expression of XIAP protein Bortezomib results in decreased expression of XIAP protein
Bortezomib results in increased expression of ZFAND2A mRNA; Bortezomib results in increased expression of ZFAND2A protein Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]; HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein] ZFAND2A protein results in decreased susceptibility to Bortezomib
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Boron inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA]
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]
[TF protein binds to Gallium] which binds to TFRC protein TFRC protein affects the uptake of [Gallium binds to TF protein] TFRC protein affects the uptake of Gallium
[TF protein binds to Gallium] which binds to TFRC protein; Gallium analog binds to TF protein TFRC protein affects the uptake of [Gallium binds to TF protein] TF protein results in increased uptake of Gallium
ixazomib inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein]; ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]
[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium; Atropine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Pertussis Toxin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Scopolamine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; tertiapin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Tropicamide inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]
[Benzethonium results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [domiphen results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [Econazole results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [malachite green results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [o,p'-DDT results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [Reserpine results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [Tamoxifen results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [tetraoctylammonium bromide results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [Tritolyl Phosphates results in decreased activity of KCNA3 protein] which results in decreased import of Thallium; [Verapamil results in decreased activity of KCNA3 protein] which results in decreased import of Thallium
2-(4-(2-(3,4-dichlorophenyl)ethyl)phenylamino)benzoic acid inhibits the reaction [Terfenadine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]]; 2-(4-(2-(3,4-dichlorophenyl)ethyl)phenylamino)benzoic acid promotes the reaction [KCNH2 protein results in increased transport of Thallium]; 8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a)quinoxalin-5(6H)-one inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; [Benzethonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [didecyldimethylammonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [diphenylguanidine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [domiphen results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [Econazole results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [malachite green results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [o,p'-DDT results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [Quinidine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [Reserpine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [Tamoxifen results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [tetraoctylammonium bromide results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [Tritolyl Phosphates results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; [Verapamil results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; Amiodarone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Amitriptyline inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; amperozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Aripiprazole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Astemizole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Bepridil inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Chlorpheniramine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Chlorpromazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; ciclopirox inhibits the reaction [Terfenadine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]]; ciclopirox promotes the reaction [KCNH2 protein results in increased transport of Thallium]; Cisapride inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Clomipramine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Clozapine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; dofetilide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Domperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Doxepin inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Droperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; E 4031 inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; eliprodil inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Fluoxetine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Fluvoxamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Haloperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Imipramine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Lidoflazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Loratadine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Maprotiline inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Mefloquine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Methadyl Acetate inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Mibefradil inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; N-(n-butyl)-(bis-fluorophenyl)methoxytropane inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Nortriptyline inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; olanzapine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Ouabain inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Pentamidine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Perphenazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Phentolamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Pimozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Propafenone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Pyrilamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Quetiapine Fumarate inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Quinidine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Ritanserin inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; sertindole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Tamoxifen inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Terfenadine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; terodiline inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Thioridazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Trifluoperazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Trifluperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; vanoxerine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Verapamil inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; vinpocetine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] KCNH2 protein results in increased transport of Thallium; KCNH2 results in increased transport of Thallium KCNH2 protein results in increased import of Thallium
[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium; [GRM8 protein results in increased activity of [KCNJ3 protein binds to KCNJ6 protein]] which results in increased transport of Thallium; Atropine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Pertussis Toxin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Scopolamine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; tertiapin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Tropicamide inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]
[cyclohexyl-(2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine results in increased activity of KCNN2 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[cyclohexyl-(2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine results in increased activity of KCNN2 protein] which results in increased import of Thallium]
[cyclohexyl-(2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine results in increased activity of KCNN3 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[cyclohexyl-(2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine results in increased activity of KCNN3 protein] which results in increased import of Thallium] [Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium]
[Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; [Benzimidazoles analog results in increased activity of KCNQ2 protein] which results in increased import of Thallium; [KCNQ2 protein binds to KCNQ3 protein] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of KCNQ2 protein] which results in increased import of Thallium 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone affects the reaction [[Potassium results in increased activity of KCNQ2 protein] which results in increased import of Thallium]; [Potassium results in increased activity of KCNQ2 protein] which results in increased import of Thallium; ezogabine affects the reaction [[Potassium results in increased activity of KCNQ2 protein] which results in increased import of Thallium] KCNQ2 protein results in increased import of Thallium
[Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; [KCNQ2 protein binds to KCNQ3 protein] which results in increased import of Thallium; [KCNQ5 protein binds to KCNQ3 protein] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ5 protein]] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of KCNQ3 protein] which results in increased import of Thallium KCNQ3 protein results in increased import of Thallium
[ezogabine results in increased activity of KCNQ4 protein] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of KCNQ4 protein] which results in increased import of Thallium KCNQ4 protein results in increased import of Thallium
KCNQ5 protein results in increased import of Thallium [KCNQ5 protein binds to KCNQ3 protein] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ5 protein]] which results in increased import of Thallium; [Quinazolinones analog results in increased activity of KCNQ5 protein] which results in increased import of Thallium
((dihydroindenyl)oxy)alkanoic acid inhibits the reaction [SLC12A5 protein results in increased import of Thallium]; Ethylmaleimide inhibits the reaction [SLC12A5 protein results in increased import of Thallium]; Furosemide inhibits the reaction [SLC12A5 protein results in increased import of Thallium]; Staurosporine inhibits the reaction [SLC12A5 protein results in increased import of Thallium]
thallium acetate results in decreased expression of ALKBH5 protein 3-deazaadenosine inhibits the reaction [thallium acetate results in decreased expression of ALKBH5 protein]; ALKBH5 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]
3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of and results in increased methylation of ATP13A3 mRNA]; 3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of ATP13A3 protein]; ALKBH5 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]; METTL14 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]; METTL3 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]; thallium acetate results in increased expression of and results in increased methylation of ATP13A3 mRNA thallium acetate results in increased stability of ATP13A3 mRNA
3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of METTL14 protein]; METTL14 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]
3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of METTL3 protein]; METTL3 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]
browse the term
